Investors of Soleno Therapeutics Now Have a Chance to Lead Fraud Lawsuit

Soleno Therapeutics Investors: A Chance for Justice

In a significant development for shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO), The Law Offices of Frank R. Cruz have announced a unique opportunity for investors who experienced losses related to the company’s recent actions. They can now take the lead in a securities fraud class action lawsuit, potentially recuperating some of their losses while holding accountable those responsible for the alleged misconduct.

This legal action stems from serious allegations against Soleno Therapeutics regarding their Phase 3 clinical trial program for DCCR (a treatment intended for individuals with Prader-Willi Syndrome). The lawsuit asserts that between March 26, 2025, and November 4, 2026, the company failed to adequately disclose critical safety concerns associated with DCCR, significantly impacting its perceived commercial viability.

Allegations Against Soleno Therapeutics

According to the complaint, the defendants—laying claim to major negligence—misrepresented key information to investors, which includes:
1. Downplayed Safety Concerns: The complaint claims there were significant evidence and concerns about safety that were not disclosed, particularly issues surrounding excess fluid retention among clinical trial participants.
2. Greater Risks Than Denoted: Due to undisclosed safety issues, the risks involved in administering DCCR to treat hyperphagia in Prader-Willi Syndrome patients may be materially higher than Rotched by the company.
3. Commercial Viability Concerns: It is alleged that DCCR had less commercial promise than previously indicated, as well as numerous undisclosed risks concerning its potential launch. These risks incorporate patient compliance, adoption rates by prescribers, potential adversities regarding regulatory actions, and related legal or reputational issues that could arise.
4. Misleading Statements: Investors were subjected to materially misleading information about Soleno's business performance and future outlook, which directly impacted their investment decisions.

Who Can Participate?

The Law Offices of Frank R. Cruz urge all investors who suffered financial losses related to Soleno Therapeutics to consider stepping forward. Those who purchased shares of SLNO and experienced a monetary loss before the deadline on May 5, 2026, are encouraged to contact the law firm for a consultation.

How to Participate

Participants can join the ongoing legal action without any immediate obligation. Investors can select the legal representation of their choosing and still remain involved in the class action, even as inactive members. Interested individuals can contact The Law Offices of Frank R. Cruz via email or phone for more detailed information regarding the lawsuit.

Contact Information

For those seeking additional details or who wish to learn more about their rights in relation to this potential class action, reach out directly to the law firm:

Conclusion

This opportunity presents a vital chance for investors who felt wronged by Soleno Therapeutics to hold the company accountable for its alleged deception. As the case unfolds, other shareholders may find similar paths to rectify their situations, thus emphasizing the need to stay informed about related developments within the company.

In an era where investor rights are being increasingly recognized, the Soleno Therapeutics case may serve as a pivotal moment in the larger conversation about corporate accountability in the healthcare sector.